The profile.

Our client (referred to here as "the founder") is the founder and CEO of a climate technology company developing direct-air capture systems for industrial-scale carbon removal. The company had raised $24M in Series A funding from major climate-focused venture firms, secured pilot deployments with two Fortune 500 industrial customers, and held 11 patents granted or pending across carbon capture chemistry and process engineering.

The founder held a PhD in chemical engineering from a top-tier U.S. institution, had published 18 peer-reviewed papers (cited 1,400+ times with documented independent citations), and had been featured in MIT Technology Review, Bloomberg Green, and a 60 Minutes segment on climate-tech founders. The company's technology had been validated by the U.S. Department of Energy's ARPA-E program and had received a federal grant under the Inflation Reduction Act's industrial decarbonization provisions.

By any standard pre-2024, the case was a slam dunk.

The strategic question.

By Q4 2025, the EB-1A landscape had changed materially. Approval rates had drifted down from the 2022 highs. RFE issuance had increased 38% from FY23 to FY25. Most importantly, the patterns of RFE issuance had shifted: officers were increasingly issuing RFEs targeting Kazarian step-two final merits — the qualitative analysis of whether the applicant truly belonged in the "small percentage at the top" — even when threshold criteria were clearly met.

For our climate tech founder, the threshold question was not seriously in dispute. The case could clearly establish: published material (criterion 3), original contributions of major significance (criterion 5), authorship of scholarly articles (criterion 6), critical role at distinguished organizations (criterion 8), and high salary (criterion 9). Five of ten criteria, with three required.

The harder question was step two. In a category increasingly populated by other accomplished climate-tech founders — many with similar Series A funding, similar press coverage, and similar academic credentials — how would our client be positioned as among the small percentage at the very top?

The construction.

We built three structural elements that addressed step-two scrutiny directly.

First, comparative evidence with named peers. Rather than describing the founder's accomplishments in isolation, the petition explicitly compared his record against five named climate-tech founders working on similar problems — by funding raised, patents granted, customer deployments achieved, media coverage breadth, and academic citation independence. The comparison was framed factually with citations to public sources for each comparator. The conclusion: across the five most directly comparable founders, our client ranked at or near the top on every measurable axis.

Second, federal recognition layered into the prong-1 case. The ARPA-E validation and IRA grant became central evidence — not for the substantive merit of the work, but as documented federal recognition that the work was important to U.S. interests. Letters from two ARPA-E program directors confirmed the founder's role in advancing federally identified priorities. These letters were carefully calibrated: substantive, independent, addressing specific contributions, written in the directors' own voices (not provided as templates).

Third, a reference letter network of 7 letters across 4 countries. All independent peer experts (no current or former employers). All addressing specific original contributions rather than general praise. All from distinguished institutions. Geographic and institutional diversity demonstrated international recognition; the letters from international peers explicitly stated the founder's standing in the global climate-tech community.

The outcome.

The petition was approved in premium processing without an RFE, with concurrent I-485 adjustment of status filed. The founder received approval notification 87 days from initial filing. The I-485 was approved 9 months later.

What this means for future applicants.

This case is reproducible. The pattern works because it addresses the actual question USCIS is asking in 2026, rather than the question applicants assume USCIS is asking. Meeting three of ten criteria is the floor, not the ceiling. The decision turns on the comparative analysis.

For applicants with strong but not Nobel-tier credentials — the vast majority of approved EB-1A petitioners — the strategic path is to:

Identify your direct comparators in your specific subfield (not your broad industry). Be honest with yourself about who they are.

Document your standing against them using public evidence: funding, awards, citations, customer deployments, media coverage breadth, patent counts. The comparison must be factual and citable.

Build the reference letter network for independence, not for prestige alone. Five independent peer letters from four different countries outperform ten letters from your current and former employers.

Address step-two directly in the petition letter, not just in the criterion-by-criterion documentation. The final merits narrative is its own document. Treat it that way.

The profile.

Our client (referred to here as "the researcher") was a senior AI safety researcher at a major U.S.-based AI lab. She held a PhD from a leading European university, had published 14 papers on alignment and interpretability with substantial independent citations, and had served as a research partner on three projects directly funded by the U.S. Department of Defense's AI safety initiatives.

By 2025 standards, her credentials read as borderline-strong for NIW — clearly accomplished, clearly contributing to AI safety, but in a field where many candidates had similar credentials. The question was not whether she was a strong researcher. The question was how to structure the case for a 2026 USCIS environment where 40% of NIW filings were being denied.

The strategic question.

The 2026 NIW environment was unforgiving on three specific failure modes: vague endeavor descriptions, missing federal policy citations, and underdeveloped balance-prong arguments. For our researcher, two of those three were potential vulnerabilities.

Endeavor specificity. "Advancing AI safety research" was the kind of broad framing that 2026 RFEs were targeting reliably. The endeavor needed to be specified at the project level, not the field level.

Federal policy alignment. AI safety as a federal priority was clear in policy documents — the National AI Initiative Act, NIST's AI Risk Management Framework, the various 2024-2025 executive orders on AI — but the petition needed to cite them specifically, not invoke them generally.

The construction.

The endeavor specification document. Before any drafting began, we built a structured articulation of the researcher's proposed endeavor: four named research projects (with abstract descriptions), three named institutional partners, specific geographic scope (U.S.-based research with international collaboration), and measurable outcomes (publications, framework releases, deployment milestones). This document became the foundation of the prong-1 argument.

The federal policy citation matrix. We identified eight specific federal documents establishing AI safety as a national priority: the National AI Initiative Act of 2020 (Public Law 116-283), the 2023 Executive Order on Safe, Secure, and Trustworthy AI, the NIST AI Risk Management Framework, the DoD AI Strategy, the National Security Memorandum on AI, the OSTP Blueprint for an AI Bill of Rights, the CHIPS Act's AI-related provisions, and the NSF's National AI Research Resource program. Each was cited in the petition letter with specific reference to which provision of the document aligned with which aspect of the researcher's work.

The reference letter strategy. Six letters total: two from independent AI safety researchers at non-affiliated institutions, two from DoD AI program officers (federal documents establishing recognition), one from a NIST collaborator, and one from a major AI lab leader unaffiliated with the researcher's employer. Each letter addressed specific contributions and tied them to specific federal priorities.

The balance prong. Rather than treating prong 3 as a conclusory paragraph, we built a 4-page argument with three subsections: urgency (AI safety priorities were time-sensitive and labor cert delays would harm them), scarcity (very few researchers had the specific combination of safety expertise + interpretability methods), and specialization (the work could not be reduced to standard labor market job descriptions).

The RFE — and the response.

The petition received a single RFE 14 weeks after filing. The RFE targeted prong 2 — specifically, the documentation of how the researcher was uniquely well-positioned to advance the proposed endeavor versus other capable AI safety researchers.

The RFE response built additional comparative evidence: a published-paper citation matrix showing the researcher's specific contributions had been built on by other researchers, a record of conference invitations as a recognized expert in alignment, and additional letters from the DoD program officers explicitly comparing her work to other contributors in the same federal initiatives.

The petition was approved 11 weeks after the RFE response was filed.

What this means for future applicants.

The 2026 NIW environment is the most demanding in the category's history. Cases that would have approved in 2022 routinely receive RFEs or denials in 2026. The difference is rarely the candidate. It's the construction.

Treat the endeavor specification as a document, not a paragraph. Four-page articulations of the proposed endeavor — with named projects, partners, scope, and metrics — fare reliably better than two-paragraph descriptions of "the field I work in."

Build the federal citation matrix before drafting. If you cannot identify five federal documents establishing your work's priority, the case needs more development before filing.

Treat balance prong as a real argument. The era of a single conclusory paragraph on prong 3 is over. Build the urgency, scarcity, or specialization argument with supporting documentation.

Plan for RFEs as part of the process, not as a sign of failure. In a 35-40% RFE environment, planning for RFE response capacity is part of the engagement, not a contingency. Strong petitions still receive targeted RFEs.

The profile.

Our client (referred to here as "the quant") had spent eight years as a senior quantitative researcher at two major U.S. hedge funds, leading the development of statistical arbitrage strategies that generated documented multi-billion-dollar returns. He held a PhD in applied mathematics, had published research on stochastic modeling in peer-reviewed journals, and had been recognized in industry rankings of top quantitative researchers.

In 2025, he was preparing to leave his employer to found his own quantitative trading firm — and needed an O-1A to do so as a self-employed founder rather than continuing as a salaried employee at a hedge fund.

The strategic question.

The threshold question — meeting three of eight O-1A criteria — was not in serious dispute. The quant could clearly document: high salary (multi-million dollar compensation), original contributions of major significance (documented trading strategies that generated returns), authorship of scholarly articles (peer-reviewed publications), critical role at distinguished organizations (senior research lead at well-known hedge funds), and arguably press coverage (industry rankings and trade publications).

The harder questions were two specific 2026 O-1A RFE patterns.

First, the "extraordinary role" question. 2026 USCIS officers were increasingly issuing RFEs targeting whether the specific work the beneficiary would perform in the U.S. actually required extraordinary ability — versus being ordinary work performed by an extraordinary person. The petition needed to articulate why the quant's planned U.S. role (founding a quantitative trading firm) specifically required his extraordinary abilities rather than being something a competent quantitative professional could do.

Second, the advisory opinion strategy. The quantitative finance field lacks a single dominant peer organization in the way that, say, the film industry has SAG-AFTRA. Strategic identification of the right consulting body — and substantive engagement with it — would materially affect the case.

The construction.

The extraordinary role argument. The petition included a dedicated section articulating why founding and leading a quantitative trading firm at the proposed scale — with the proposed strategies, the proposed risk frameworks, and the proposed regulatory positioning — specifically required the quant's combination of mathematical sophistication, market experience, and proven track record. The argument drew explicit contrasts: a competent quantitative analyst could execute strategies, but designing the firm's investment philosophy, building the regulatory infrastructure for a new fund structure, and leading the team required the documented original contributions that distinguished the quant's career.

The advisory opinion engagement. Rather than approaching a generic finance industry body, we engaged with the Financial Engineering Association (a specialized academic-industry hybrid body in quantitative finance) and requested a substantive advisory opinion. We provided complete documentation of the quant's accomplishments and the proposed U.S. role. The resulting opinion was 6 pages of substantive analysis specifically addressing both the extraordinary ability and the extraordinary nature of the proposed role.

The itinerary specificity. The petition included a detailed itinerary covering 18 months: incorporation timeline, regulatory registration milestones, initial capital deployment, strategy development phases, and team building stages. The itinerary was supported by signed agreements with initial seed investors and a documented relationship with a prime broker.

The reference letter network. Five letters total: three from independent academic experts in quantitative finance at distinguished universities, one from a former hedge fund CEO (unaffiliated with the quant's recent employers), and one from a SEC-registered compliance expert addressing the quant's understanding of the regulatory framework.

The outcome.

The O-1A was approved without an RFE. The quant launched his firm three months after approval. We are now building toward an EB-1A filing approximately 24 months out — and the documentation strategy at the O-1A stage was designed from day one to support that future filing.

What this means for future applicants.

Founder O-1A petitions face specific 2026 patterns that didn't dominate adjudication five years ago. Three takeaways:

Address the extraordinary role question explicitly in your petition letter. Don't assume USCIS will infer it. State directly why the specific role you'll perform requires extraordinary ability rather than competent professional execution.

Treat the advisory opinion as a strategic asset, not a procedural box. Identify the right consulting body for your field. Engage substantively. Request a detailed opinion. Generic favorable opinions are weak evidence; substantive opinions addressing your specific qualifications are strong evidence.

Build the O-1A documentation to support the eventual EB-1A. If you'll seek a green card later, the case structure decisions at the O-1A stage directly affect the strength of the eventual EB-1A. Building backward from the EB-1A is the strategic play.

The profile.

Our client (referred to here as "the filmmaker") was a documentary director and producer with a body of work spanning festival features, streaming series, and short-form journalism documentary. Her most recent feature had won jury prizes at two A-list international festivals, been acquired for global streaming distribution by a major platform, and received substantive reviews in Variety, The Hollywood Reporter, and IndieWire. She had directed five feature documentaries and produced two streaming series across an 11-year career.

She was seeking O-1B status to direct a U.S.-based documentary series for a major streaming platform — a project that had received green light commitment but couldn't proceed without her authorized to work in the United States.

The strategic question.

The O-1B for filmmakers presents a structural question that's gotten more complicated in the streaming era: should the petition be filed under the arts "distinction" standard (lower bar, broader evidence categories) or the motion picture and television "extraordinary achievement" standard (higher bar, more specific evidence requirements)?

For a documentary filmmaker whose work spans theatrical festival distribution and streaming platform distribution, both standards potentially apply. The strategic decision affects what evidence is required, how it's framed, and what threshold USCIS will apply.

We chose MPTV. Three reasons:

The substantive work was MPTV. The petition was for a streaming documentary series — clearly motion picture and television work. Filing under the arts standard for clearly MPTV work would have been vulnerable to RFE on the framing question itself.

The evidence supported the higher standard. Festival jury prizes at A-list festivals, major streaming acquisition deals, and critical reception in MPTV-focused trade publications collectively built a strong "extraordinary achievement" record. The case wouldn't survive on the distinction standard alone but did meet the higher bar.

It established the precedent for future filings. If the filmmaker eventually filed EB-1A, the MPTV framing would carry forward. Filing O-1B under arts first and EB-1A later under MPTV would create awkward inconsistency.

The construction.

The festival circuit evidence. Documentation of both jury prizes — official certificates, festival programs, juror identification, jury statements, press coverage of the awards. Festival credentials are central to documentary careers, and the petition treated them with appropriate weight.

The streaming success documentation. Subscribers reached, hours watched, completion rates, and country availability for the streaming acquisition — all sourced from platform documentation rather than self-reported figures. Because streaming platforms have become reluctant to share raw subscriber-level data, we worked with the platform's licensing team to obtain a substantive verification letter addressing the documentary's performance on the platform.

The critical reception package. Curated press coverage from major MPTV trade publications. We focused on substantive features rather than mentions — three Variety pieces specifically about the filmmaker, a Hollywood Reporter feature on documentary directors of her generation, two IndieWire reviews of her work, and coverage in the New York Times documentary roundup. All curated for substance and independence (no PR-initiated coverage included).

The advisory opinion strategy. The Directors Guild of America provided a peer organization consultation. We engaged with the DGA's documentary committee specifically, provided complete documentation of the filmmaker's work, and obtained a 4-page substantive opinion addressing her record under the MPTV standard.

The comparable evidence for cross-platform work. Where standard MPTV evidence categories didn't cleanly fit certain projects (a short-form documentary series for an online platform, a podcast documentary with associated visual content), we built comparable evidence with platform metrics, audience reach data, and industry coverage in publications covering the medium.

The outcome.

What this means for future applicants.

O-1B in the streaming era requires choices that didn't exist when the regulations were written. Three takeaways:

Choose the standard deliberately, not by default. For documentary, hybrid, and streaming-era filmmakers, the arts vs MPTV decision is strategic. Make it consciously, document the reasoning, and build the evidence to support the chosen standard.

Streaming success requires platform engagement. Self-reported subscriber numbers and hours-watched figures rarely satisfy USCIS scrutiny. Work with the streaming platform's licensing or partnerships team to obtain substantive verification letters or official performance documentation.

Curate critical reception for substance. Five substantive features in major MPTV trade publications outweigh fifty mentions in roundups. Quality beats quantity. Independence beats PR-initiated coverage.

Engage the advisory body specifically for your field. The DGA's documentary committee provides different substance than a general DGA consultation. Find the right sub-body for your specific medium.

The profile.

Our client (referred to here as "the executive") joined our practice in mid-2023 as Chief Scientific Officer of a clinical-stage biotech company developing therapies for rare neurological disorders. He held a PhD in molecular biology from a top-tier institution, had authored 22 peer-reviewed publications, was named inventor on 8 patents, and had led the scientific strategy for two FDA-approved therapeutics earlier in his career.

By any pre-2024 measure, his accomplishments arguably supported a direct EB-1A filing. But the strategic question wasn't whether he could file EB-1A. It was whether he should.

The strategic question.

We recommended O-1A first, with explicit case construction designed to strengthen an eventual EB-1A filing 24-36 months later. The reasoning:

The EB-1A final merits bar was rising. Even in mid-2023, we could see the patterns shifting. Borderline cases that would have been approved in 2021 were getting RFEs. Strong cases were getting RFEs on step two. Direct EB-1A filing for the executive — while feasible — carried meaningful RFE risk that would extend the timeline by 8-12 months.

The executive's U.S. role was already strong and getting stronger. Two FDA-approved therapeutics on his record was strong but historical. His current role had recently transitioned from "newly appointed CSO" to "CSO who has now overseen [specific deliverables]." The accomplishments at his current company would substantially strengthen the case if we let them mature for 24 months.

O-1A offered immediate status with no real disadvantage. The visa would let him work in the U.S. immediately, with no employer sponsorship gating his career choices. The downside of filing O-1A first was almost zero. The upside — a stronger EB-1A position later — was substantial.

The O-1A construction.

We filed the O-1A in Q3 2023. The case documented six of eight criteria robustly, with the U.S. role at his current company framed as critical (criterion 7) and substantively connected to his prior FDA approval work to demonstrate continuity of impact.

Crucially, the O-1A petition was constructed with the eventual EB-1A in mind:

Reference letters were drafted to support both cases. Letters from independent experts addressed both the immediate O-1A standard and the deeper EB-1A "small percentage at the top" standard. The letters would not need to be redrafted from scratch for the EB-1A — they would be supplemented and updated.

The evidence inventory was structured for evolution. Patent documentation, FDA approval references, and publications were organized in a structured catalog that would grow over the 24 months between filings rather than be rebuilt from scratch.

The U.S. role documentation was designed to compound. Each project, presentation, recognition, and publication during the O-1A period was documented contemporaneously with the eventual EB-1A in mind.

The O-1A was approved 3.5 months after filing, without RFE.

The EB-1A construction.

27 months later, in late 2025, we filed the EB-1A. The case structure built directly on the foundation laid in 2023:

The reference letters were updated, not rebuilt. Five of the original O-1A letter writers provided updated letters addressing the executive's accomplishments during the intervening 27 months. Two new letters were added from researchers who had emerged as significant figures in the field during the O-1A period.

The evidence inventory had compounded. The 22 publications from 2023 had become 26. The 8 patents had become 11. The two FDA approvals from prior had become three (the executive's current company received its first FDA approval during the O-1A period). The "leading role" documentation had matured from "newly appointed" to "led for three years."

The comparative positioning was now defensible at step two. The 27 months had allowed building of explicit comparative evidence — the executive could now be positioned against named peers in the rare neurological therapeutics field with specific factual comparisons on publications, patents, FDA approvals, and citation metrics. This was the step-two evidence base that had not been mature enough in 2023.

The EB-1A was approved 4 months after filing, without RFE, in regular processing.

The outcome.

What this means for future applicants.

The O-1A-first strategy is underused. Most applicants — and many firms — default to either "I'll file EB-1A because I qualify" or "I'll file O-1A because it's safer." Both framings miss the strategic question.

The real question is timing. If you would file EB-1A today and your case is borderline at step two, filing O-1A first and letting your evidence mature for 18-30 months often yields a stronger eventual EB-1A with less RFE risk and similar total cost.

The evidence inventory matters more than the immediate filing decision. What you document, how you structure it, and how you build it over time is more strategically important than whether you file O-1A or EB-1A in the next 90 days.

Treat the O-1A as Year One of a multi-year strategy, not as a standalone product. Reference letter sources, evidence catalogs, and U.S. role documentation should all be designed with the eventual EB-1A in mind from day one.